We are live on
!
Find out more
CP
Covenant Partners Portfolio holdings
AUM
$342M
1-Year Est. Return
19.24%
This Fund
S&P 500
This Quarter
Est. Return
+6.32%
1 Year Est. Return
+19.24%
3 Year Est. Return
+70.32%
5 Year Est. Return
+79.29%
10 Year Est. Return
–
AUM
$265M
AUM Growth
+$13.8M
(+5.5%)
Cap. Flow
-$371K
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
49.35%
Holding
208
New
7
Increased
11
Reduced
28
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI EAFE Value ETF
EFV
|
+$930K |
| 2 |
Unilever
UL
|
+$381K |
| 3 |
iShares MSCI EAFE Growth ETF
EFG
|
+$367K |
| 4 |
DexCom
DXCM
|
+$322K |
| 5 |
Floor & Decor
FND
|
+$290K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Takeda Pharmaceutical
TAK
|
+$487K |
| 2 |
Verizon
VZ
|
+$317K |
| 3 |
SPLK
Splunk Inc
SPLK
|
+$314K |
| 4 |
Novartis
NVS
|
+$292K |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$231K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.39% |
| 2 | Healthcare | 8.06% |
| 3 | Financials | 7.83% |
| 4 | Consumer Discretionary | 6.21% |
| 5 | Industrials | 6.05% |
Similar funds
SHFA
YCG
TAM
LODC
OFS
MWM
PPH
TPW
Covenant Partners's Q2 2021 Portfolio in Review
As of Q2 2021, Covenant Partners held 208 positions worth $265M, up 5.5% from $251M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Covenant Partners's Q2 2021 filing shows 7 new, 11 increased, 28 reduced and 7 closed positions. Its largest new stake was Unilever: 5,724 shares worth $377K. The largest sale was Takeda Pharmaceutical, an estimated $487K.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Covenant Partners's largest Q2 2021 buy was Unilever: 5,724 shares worth $377K.
- Covenant Partners added most to iShares MSCI EAFE Value ETF in Q2 2021, an estimated $930K increase.
- Covenant Partners's biggest Q2 2021 reduction was Takeda Pharmaceutical, cutting an estimated $487K.
- Covenant Partners fully exited BioMarin Pharmaceuticals in Q2 2021, selling an estimated $231K.
- Covenant Partners's ten largest holdings make up 49% of its $265M portfolio in Q2 2021.
- Covenant Partners opened 7 new positions and closed 7 in Q2 2021.
- Covenant Partners's portfolio value rose 5.5% quarter-over-quarter to $265M.
Based on Covenant Partners's 13F filing for Q2 2021, filed 2 Aug 2021.